

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.

Claims 2-3 (Canceled).

Claim 4 (Previously Presented): A medicinal composition comprising an effective amount of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof and a pharmaceutically acceptable carrier.

Claims 5-6 (Canceled).

Claim 7 (Currently amended): A method for the treatment of a microbial infection which comprises administering an effective amount of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof to a patient in need thereof.

Claim 8 (Previously Presented): The compound according to claim 1, wherein said compound is an acid addition salt in a base addition salt.

Claim 9 (Previously Presented): The compound according to claim 1, wherein said compound is an acid addition salt.

Claim 10 (Previously Presented): The compound according to claim 1, wherein said compound is an acid addition salt selected from the group consisting of maleate, methane-sulfonate, p-toluene sulfonate and hydrochloride.

Claim 11 (Previously Presented): The method according to claim 7, wherein the daily dosage is from about 0.1 to 1000 mg/kg.

Claim 12 (Previously Presented): The method according to claim 7, wherein the daily dosage is from about 0.5 to 100 mg/kg.

Claim 13 (New) The method according to claim 7, wherein the microbial infection is a bacterial infection.

Claim 14 (New) The method according to claim 13, wherein the bacterial infection is a pneumococci infection.

Application No. 10/019,436
Reply to Office Action of August 8, 2003

DISCUSSION OF THE AMENDMENT

Claims 2, 3 and 5 have been canceled. Claim 7 has been amended by adding --to a patient in need thereof-- at the end thereof. New Claims 13 -14 have been added, limiting the microbial infection to --a bacterial infection--, and to --a pneumococci infection--, respectively, as supported in the specification at page 23, line 7ff.

No new matter has been added. Claims 1, 4 and 7-14 are now pending in the application.